| Literature DB >> 28742076 |
J Nagy1, J Kobolák2, S Berzsenyi1, Z Ábrahám1, H X Avci2, I Bock2, Z Bekes1, B Hodoscsek1, A Chandrasekaran2, A Téglási2, P Dezső1, B Koványi1, E T Vörös1, L Fodor1, T Szél1, K Németh3, A Balázs3, A Dinnyés2, B Lendvai1, G Lévay1, V Román1.
Abstract
The aim of the present study was to establish an in vitro Kleefstra syndrome (KS) disease model using the human induced pluripotent stem cell (hiPSC) technology. Previously, an autism spectrum disorder (ASD) patient with Kleefstra syndrome (KS-ASD) carrying a deleterious premature termination codon mutation in the EHMT1 gene was identified. Patient specific hiPSCs generated from peripheral blood mononuclear cells of the KS-ASD patient were differentiated into post-mitotic cortical neurons. Lower levels of EHMT1 mRNA as well as protein expression were confirmed in these cells. Morphological analysis on neuronal cells differentiated from the KS-ASD patient-derived hiPSC clones showed significantly shorter neurites and reduced arborization compared to cells generated from healthy controls. Moreover, density of dendritic protrusions of neuronal cells derived from KS-ASD hiPSCs was lower than that of control cells. Synaptic connections and spontaneous neuronal activity measured by live cell calcium imaging could be detected after 5 weeks of differentiation, when KS-ASD cells exhibited higher sensitivity of calcium responses to acetylcholine stimulation indicating a lower nicotinic cholinergic tone at baseline condition in KS-ASD cells. In addition, gene expression profiling of differentiated neuronal cells from the KS-ASD patient revealed higher expression of proliferation-related genes and lower mRNA levels of genes involved in neuronal maturation and migration. Our data demonstrate anomalous neuronal morphology, functional activity and gene expression in KS-ASD patient-specific hiPSC-derived neuronal cultures, which offers an in vitro system that contributes to a better understanding of KS and potentially other neurodevelopmental disorders including ASD.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28742076 PMCID: PMC5538124 DOI: 10.1038/tp.2017.144
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Figure 1Neurons differentiated from human induced pluripotent stem cell (hiPSC)-derived neuronal precursor cells (NPCs). Representative images of CTL1, CTL2 and KS-ASD cells expressing the neuronal markers class III beta-tubulin (TUJ), Neurofilament 200 (NF200), and microtubule-associated proteins TAU and MAP2 on day 35 of terminal differentiation. The neurons are also positive for the glutamatergic subtype-specific marker vesicular neurotransmitter transporter 1/2 (vGLUT1/2). Insets highlight the magnified regions of cells immunolabeled for vGlut1/2. Nuclei are counterstained with DAPI. Scale bars=50 μm. KS-ASD, Autism spectrum disorder patient with Kleefstra syndrome.
Figure 2Physiologically active neurons differentiated from human induced pluripotent stem cell (hiPSC)-derived NPCs. (a) Expression of presynaptic protein Synapsin1 in MAP2-positive neuronal cells. Scale bar=10 μm. (b) Representative graphs of electrophysiological recordings of Na+ and K+ currents, Bicuculline-sensitive GABA-mediated response and evoked action potentials in 8-week-old hiPSC-derived CTL1 neurons. (c) Spontaneous calcium oscillations are more apparent in 8-week-old neurons than in 3-week-old neuronal cultures. Left, representative Ca2+-transients of individual neurons; right, quantification of Ca2+-transients 3 and 8 weeks after terminal differentiation. t-test, *P<0.0001. (d) Presence of synaptic cleft (arrow) and presynaptic vesicles (arrowhead) was verified by electron microscope imaging in 5-week-old hiPSC-derived neurons. Scale bar=500 nm.
Figure 3Reduced EHMT1 mRNA expression and altered gene expression in human induced pluripotent stem cell (hiPSC)-derived neuronal cells from KS-ASD patient on day 10 of terminal differentiation. (a) The mRNA level of EHMT1 transcript variant 1 is reduced in KS-ASD cells compared to CTL1 and CTL2 cells, whereas no change in the level of EHMT1 transcript variant 2 is observed in KS-ASD vs control cells. t-test, CTL1 vs KS-ASD *P=0.0061; CTL2 vs KS-ASD #P=0.0111. Right panel, Western blot analysis of EHMT1 protein expression in CTL1, CTL2 and KS-ASD neurons. GAPDH was used as protein-loading control. (b) Gene expression changes in KS-ASD neurons compared to CTL1 (left) or CTL2 (right) neuronal cells on day 10 of terminal differentiation. Mann–Whitney test, *P<0.05, **P<0.005.
Figure 4Impaired neurite morphology of hiPSC-derived neuronal cells from KS-ASD patient. (a) Neurite tracing of the neuronal cells labeled for MAP2 on day 10 of terminal differentiation. Scale bar=50 μm. (b) Quantification of the number of MAP2-positive neuronal cells and parameters of neurite morphology of cells from KS-ASD and controls on day 10 of terminal differentiation. The results of the measurements are presented as mean data set of the two cells lines per KS-ASD, CTL1 and CTL2. Mann–Whitney test, *P<0.05 in KS-ASD vs CTL1, #P<0.05 in KS-ASD vs CTL2. (c) Graph representing decreased number of dendritic protrusions on neuronal cells from KS-ASD patient on day 14 of terminal differentiation. Mann–Whitney test, *P<0.05 in KS-ASD vs CTL1, #P<0.05 in KS-ASD vs CTL2. Arrowheads on the photograph point to dendritic protrusions. Scale bar=10 μm.
Figure 5Increased acetylcholine-evoked calcium signal in neuronal cells differentiated from KS-ASD patient-derived hiPSCs. (a) Expression of Nicotinic Acetylcholine Receptor beta 2 (AChRB2, green) in MAP2-positive 4-week-old hiPSC-derived nerurons. Scale bar=20 μm. (b) Change in fluorescence intensity upon administration of glutamate (Glu) or acetylcholine (ACh) onto 8-week-old control (CTL1) and KS-ASD neurons pre-loaded with Calcium 6-QF dye. Scale bar=50 μm. (c) Representative graphs showing Glu and ACh-evoked Ca-transients in CTL1 and KS-ASD neurons. Right panels, quantification of the Ca2+-responses as the mean of maximal intensity of the responses after treating the cells with Glu (upper) or ACh (lower). t-test, *P<0.05. KS-ASD, Autism spectrum disorder patient with Kleefstra syndrome.